An interventional study of altitude exposure in Effect of High Altitude, sponsored by University of Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-17.
Sponsored by University of Zurich · Not applicable, Interventional, and Prevention
Prospective interventional trial in lowlanders evaluating the effect of acute exposure, acclimatization and re-exposure to high altitude on cerebral autoregulation
Baseline measurements will be performed in Santiago de Chile, 520 m, over the course of 3 days. Participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the ALMA base camp located at 2900 m near San Pedro de Atacama, northern Chile. Participants will stay there for the next 8 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing testing as described above at the first and the last day at 5050m. Daily transports from 2900 to 5050 m will be by car (1 h ride, one way). After the first 8 day altitude sojourn participants will return to the Santiago area (520 m) for a 6 day recovery period.
A second altitude sojourn with an identical schedule as the one described above and a final low altitude stay of 3 days will follow.
189 studies on the registry are indexed under Altitude Sickness; 44 are open to participants now.
This study's enrollment of 21 is below the median of 33 across 157 interventional studies indexed under Altitude Sickness.
Browse Altitude Sickness studies →University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
Other: altitude exposure
altitude exposure
Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
Change in magnitude of the coefficient of coherence between blood flow velocity in the middle cerebral artery measured by transcranial ultrasound Doppler and systemic blood pressure at day 2 (5050 m) vs. day 1 (520 m) of the first cycle
Time frame: day 1; day 2 first cycle
Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
Change in magnitude of the coefficient of coherence between blood flow velocity in the middle cerebral artery measured by transcranial ultrasound Doppler and systemic blood pressure at day 7 (5050 m) vs. day 1 (520 m) of the first cycle.
Time frame: day 1; day 7 first cycle
Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
Change in magnitude of the coefficient of coherence between blood flow velocity in the middle cerebral artery measured by transcranial ultrasound Doppler and systemic blood pressure at day 7 (5050 m) vs. day 2 (5050 m) of the second cycle.
Time frame: day 2; day 7 second cycle
Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
Change in magnitude of the coefficient of coherence between blood flow velocity in the middle cerebral artery measured by transcranial ultrasound Doppler and systemic blood pressure at day 2 (5050 m) second cycle vs. day 2 (5050 m) of the first cycle.
Time frame: day 2 first cycle; day 2 second cycle
Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
Change in magnitude of the coefficient of coherence between blood flow velocity in the middle cerebral artery measured by transcranial ultrasound Doppler and systemic blood pressure at day 7 (5050 m) second cycle vs. day 7 (5050 m) of the first cycle.
Time frame: day 7 first cycle; day 7 second cycle
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich